The Cooper Companies, Inc.

(NASDAQ Global Select)
Back to all articles
Slightly Bullish +19

A Look At Cooper Companies (COO) Valuation As Shares Face Recent Price Pressure

AI-generated analysis

πŸ“‰ Cooper Companies (COO) shares faced price pressure recently, declining 9% over the past month and 17% over the past three months.

πŸ’Ό The company operates through two main business units: CooperVision generating $2.79 billion and CooperSurgical contributing $1.36 billion.

🌍 Revenue was distributed across regions with US$2.75 billion from the United States and US$2.42 billion from Europe.

πŸ“ˆ Financial performance showed annual revenue growth of 5.1% and net income growth of 16.6%, totaling $401.4 million in net income on $4.15 billion of revenue.

πŸ“‰ Recent trading momentum is fading with a 3-year total shareholder return of 25.1% and a 5-year return of 28.7%.

🏦 Analysts estimate a fair value of US$91.80 per share, which suggests the current price of $69.66 could be undervalued.

πŸ’° Free cash flow is expected to increase as capital expenditure cycles wind down, with management guiding for approximately $2 billion in free cash flow over three years.

⚠️ The valuation narrative hinges on MyDAY capacity ramp efficiency and maintaining demand for fertility products and PARAGARD.

πŸ“Š Cooper Companies currently trades at a P/E ratio of 33.9x, which is higher than peers at 22.2x and the US medical equipment average of 26.7x.

βš–οΈ Investors must decide if the premium valuation reflects confidence in future earnings or pricing in expectations that are already known.

πŸ” Simply Wall St suggests checking out related content including 37 healthcare AI stocks, 13 dividend fortresses, and 61 high quality undervalued stocks.

⚑ This analysis is based on historical data and analyst forecasts without taking into account recent price-sensitive announcements or qualitative material.

Bullish Signals
  • Cooper Companies reported net income of US$401.4m alongside annual revenue of US$4.15b, demonstrating strong financial performance.
  • The company achieved positive growth with a reported annual revenue increase of 5.1% and net income growth of 16.6%.
  • Management guides for approximately $2 billion in free cash flow over the next three years, reflecting confidence in future cash generation.
  • Free cash flow is expected to improve as a multi-year capital expenditure cycle winds down following the ramp-up of MyDAY capacity.
  • The company's fair value is estimated at $91.80, significantly above the recent close of $69.66, indicating potential upside potential.
  • Improved cash generation will support debt reduction and share repurchases, further benefiting shareholders.
Risk Factors
  • Shares have faced sustained downward pressure, declining approximately 9% over the past month and roughly 17% over the past 3 months.
  • The current stock price of US$69.66 is significantly below the analyst-led fair value estimate of $91.80, suggesting potential downside if expectations are not met.
  • Cooper Companies trades at a P/E ratio of 33.9x, which is well above peers at 22.2x and the US Medical Equipment average of 26.7x, indicating limited room for error if growth underdelivers.
  • Future valuation upside hinges on MyDAY's capacity ramp converting efficiently into sustained sales and fertility/PARAGARD demand not weakening further, which are uncertain risks.
  • The high valuation premium may reflect overconfidence in future earnings or suggest the market is paying too much for already known expectations.
  • If growth assumptions underperform, the current P/E multiple leaves no margin for error compared to industry peers.
Full Analysis
Cooper Companies (COO) has experienced recent share price pressure, declining 0.9% over the past day and roughly 17% over the last three months, with prices recently closing at US$69.66 and a market value of approximately US$13.7 billion. The healthcare corporation operates through two primary business units: CooperVision (CVI), which generated US$2.79 billion in revenue focused on contact lenses for conditions including astigmatism, presbyopia, and myopia; and CooperSurgical (CSI), contributing US$1.36 billion in revenue related to women's and family health products such as fertility services, medical devices, contraception, and cryostorage. Geographically, the company reported annual revenues of US$2.75 billion from the United States and US$2.42 billion from Europe, resulting in a total annual revenue of US$4.15 billion with reported net income growth of 16.6% to reach US$401.4 million. Despite these fundamentals showing revenue growth of 5.1%, recent trading momentum is fading compared to longer-term historical returns, which show a three-year total shareholder return of 25.1% and a five-year return of 28.7%. While some analyst narratives suggest a fair value price of US$91.80 based on forecasts for earnings, margins, and buybacks that would imply the stock is undervalued, the current price-to-earnings (P/E) ratio of 33.9x significantly exceeds industry peers at 22.2x, the US medical equipment average of 26.7x, and even a fair multiple of 28.2x. This premium suggests that while improved cash generation is anticipated with free cash flow projected around US$2 billion over the next three years as capital expenditures wind down following the MyDAY capacity ramp, the valuation gap requires precise alignment between growth expectations, profitability, and share count reduction. Investors are advised to consider key risks to the upside potential, specifically whether MyDAY's ramp converts efficiently into sustained sales and if demand for fertility products and PARAGARD continues without weakening, as these factors could derail the anticipated fair value narrative. The company's high P/E multiple also means there is less room for error if growth underdelivers compared to peers. Simply Wall St suggests that amidst this valuation uncertainty, investors looking to reassess healthcare exposure might consider widening their search to other healthcare AI stocks, dividend fortresses, high-quality undervalued stocks, or resilient companies with low risk scores, noting that the analysis is based on historical data and analyst forecasts without constituting a direct recommendation to buy or sell.